The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

Variations in the use of antidementia and antipsychotic drugs for nursing home residents with dementia across the United ...

The following is a summary of “SGLT2 Inhibitor Use and Risk of Dementia and Parkinson’s Disease Among Patients With Type 2 ...

The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.

Among the adverse effects reported in the trial, infusion-related reactions were observed in 26.4% of patients in the ...

A new study, however by the universities of Manchester, Nottingham, Edinburgh and Dundee, published in the BMJ, has found that antipsychotic drugs prescribed to dementia patients cause more ... light ...

In a recent study conducted by researchers from Hong Kong, evidence has emerged suggesting that your cholesterol medication ...

The European Medicines Agency’s human medicines committee is re-examining the marketing authorisation application for the ...

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in the journal Alzheimer's & Dementia, a team of researchers report the ...

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version ...

There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to ...